APA (7th ed.) Citation

MP, S., M, B., MA, W., P, D., GL, B., JM, F., . . . JG, W. (2022). Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): A multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet (London, England), 400(10367), 1927. https://doi.org/10.1016/S0140-6736(22)02034-7

Chicago Style (17th ed.) Citation

MP, Schlaich, et al. "Dual Endothelin Antagonist Aprocitentan for Resistant Hypertension (PRECISION): A Multicentre, Blinded, Randomised, Parallel-group, Phase 3 Trial." Lancet (London, England) 400, no. 10367 (2022): 1927. https://doi.org/10.1016/S0140-6736(22)02034-7.

MLA (9th ed.) Citation

MP, Schlaich, et al. "Dual Endothelin Antagonist Aprocitentan for Resistant Hypertension (PRECISION): A Multicentre, Blinded, Randomised, Parallel-group, Phase 3 Trial." Lancet (London, England), vol. 400, no. 10367, 2022, p. 1927, https://doi.org/10.1016/S0140-6736(22)02034-7.